| Literature DB >> 35948653 |
Aleksandra Stasiak1, Ewelina Perdas2, Elżbieta Smolewska3.
Abstract
Pediatric multi-system inflammatory syndrome temporally associated with COVID-19 (PIMS-TS) is a serious complication of a previous SARS-CoV-2 infection. The disease causes multiple organ failure, but in some patients, a more severe course of the disease is observed. The treatment is multidirectional and depends on the severity and course of the disease, as some patients do not respond to the recommended treatment. The aim of this study was to identify laboratory risk factors affecting the more severe course of the disease and resistance to standard therapy. It is a single-center retrospective study considering 51 patients with PIMS-TS. Clinical features, laboratory results, and additional imaging tests data were taken into account. Fifty-one patients with PIMS-TS were hospitalized within a 16-month observation period. In the studied group, 26/51 children (51%) were girls. The mean age of patients was 7 years. Sex of the patient was not a risk factor for changes in cardiovascular system or severe course of the disease. Sixteen patients (31.3%) required transfer to the intensive care unit. Children with initially higher concentrations of NT-proBNP, troponin, creatinine, triglycerides, C-reactive protein, procalcitonin, ferritin, D-dimers and lower hematocrit, platelet count, lymphocytes, and ejection fraction should be strictly observed as they have a higher risk of severe course of the disease.Entities:
Keywords: Child; PIMS; Risk factors; SARS-CoV-2
Year: 2022 PMID: 35948653 PMCID: PMC9364844 DOI: 10.1007/s00431-022-04584-8
Source DB: PubMed Journal: Eur J Pediatr ISSN: 0340-6199 Impact factor: 3.860
Fig. 1Parameters correlating with the more severe course of the disease (transfer of the child to the ICU). 1—patients who required ICU care; 2—patients who did not require ICU care. CRP, C-reactive protein; EF, ejection fraction; TG, triglycerides
Statistically significant indicators for immunoglobulin resistance in children with PIMS-TS
| NT-proBNP [pg/ml] | 985 | 249 | 2544 | 5201 | 685 | 24,981 | |||
| Troponin I [ng/ml] | 0.006 | 0.001 | 0.014 | 0.051 | 0.014 | 0.259 | |||
| Platelet count [thou/ul] | 309 | 226 | 484 | 108 | 86 | 160 | |||
| Leukocytes [thou/ul] | 11.44 | 10.20 | 18.23 | 8.41 | 5.42 | 13.50 | |||
| Lymphocytes [thou/ul] | 1.99 | 0.99 | 2.98 | 0.82 | 0.54 | 1.45 | |||
| CRP [mg/l] | 140 | 91 | 253 | 219 | 172 | 289 | |||
| Procalcitonin [ng/ml] | 1.41 | 0.42 | 1.92 | 6.63 | 3.70 | 16.05 | |||
| Lactates [mmol/l] | 1.68 | 1.00 | 2.19 | 2.49 | 1.76 | 3.01 | |||
| Sodium [mmol/l] | 138 | 136 | 140 | 136 | 132 | 137 | |||
| Ferritin [ug/l] | 226 | 130 | 400 | 578 | 296 | 1729 | |||
| D-Dimers [ng/ml] | 1758 | 856 | 3579 | 4240 | 2638 | 6301 | |||
| Creatinine [mg/dl] | 0.48 | 0.45 | 0.56 | 0.67 | 0.53 | 0.85 | |||
| Albumin[g/dl] | 3.50 | 3.00 | 3.90 | 2.90 | 2.70 | 3.00 | |||
| EF [%] | 58 | 51 | 65 | 67.5 | 65 | 71 |
Group 1, patients who only required administration of IVIG; group 2, patients who required additional treatment (steroids, biological agents)
CRP C-reactive protein, EF ejection fraction